Many have quoted and shown this image of Ankylosing Spondylitis in a young military recruit at age 25, 35, 45, 50 & 51yrs. This may be the MOST used slide in rheum! It comes from the work of Toronto's Dr. Hugh Little, who sadly passed away at age 58 yrs. https… https://t.co/G28YlyhX3v

Challenges in Lupus: -Mortality greatest in 1st yr -Dx Delays 6.4 yrs -Long-term complications increased 50 fold -Steroids worsen long-term outcomes -Health care costs increased 3 to 5 years prior to Dx -Mean delay in drug starts after Dx =177 days https://t.co/NPxzluJJAV https://t.co/J2uLOfeijV

NEJM Clinical Images: 74-yoF with psoriatic arthritis has swelling of the fifth finger; found to have nontender, subcutaneous nodules in the hypothenar region and over the fifth finger. https://t.co/ugfFGZ0CWh https://t.co/a5q1TWRqMM

Best of 2022: Undifferentiated Arthritis Does Not Follow an RA Course https://t.co/gKzIPuIbAB https://t.co/SI1RubDi5Y

Best of 2022: Acne with JAK Inhibitors https://t.co/ul0CJUTFZE https://t.co/dahLh04k4u

Infection in lupus is suggested by very high CRP, PMN-lymph ratio (NLR) Plt-lymph ratio(PLR). Study of 104 hospitalized SLE found all very high w/ infx & Combined cutoffs of CRP >20 mg/L, NLR >3.5, PLR >151 had 87 sensitivity & 81% specificity for infx https://t.co/2ycSGhnHeK https://t.co/VZsGAK2hFs

NEJM has published results of 2 phase 3 trials (BRAVE-AA1, BRAVE-AA2) demonstrating the efficacy of Baricitinib in aduls with severe alopecia areata - BARI was superior to placebo in hair regrowth by week 36 https://t.co/eTP2d107ti https://t.co/BMKrL5NLyg

New Hope for Hand Osteoarthritis The drug talarozole – which increases retinoic acid – could be a promising new treatment for hand osteoarthritis. https://t.co/jVMLiJLnch https://t.co/0nk8WA2k1S

Best of 2022: Methotrexate in PsA Until the publication of the SEAM trial1, evidence in the medical literature for the efficacy of the most commonly used drug for PsA worldwide, MTX, has been lukewarm at best. https://t.co/vl2u9JENpt https://t.co/SHHAfkFX9k

anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/hjXEopji6r https://t.co/FwzBa2YNzb

On Wednesday 12/21 the FDA approved tocilizumab (Actemra; 8 mg/kg, 60-min IV infusion ) for hospitalized COVID-19 on steroids, supplemental O2 & req ventilation, or ECMO; 1st MAb approved for COVID-19; Prev EUA issued in June 2021 https://t.co/BswLu4ZY5O https://t.co/7gpPkeoPZ4